Fluicell × Ambusol
In collaboration with Ambusol, we are leveraging Fluicell’s unique open volume microfluidic technology to create new ways to treat cancer. Together, we are working to create high precession solutions to one of the leading causes of death in the world.
Treating cancer with precision
Fluicell and Ambusol are partnering to create precise therapeutic solutions to treat cancer. The collaboration will leverage Fluicell’s proprietary microfluidic technology and Ambusol’s cancer expertise to develop a novel cancer treatment solution based on high precision delivery of therapeutic agents directly to the tumor environment, combined with simultaneous removal of oncogenic debris.
The partnership covers five important cancer indications: glioblastoma, prostate cancer, breast cancer, skin cancer, and pancreatic cancer. Development will initially focus on glioblastoma, a highly aggressive form of brain cancer that affects approximately 300,000 people each year. As part of the collaboration, Fluicell is developing a catheter device using the company’s recirculation technology that is capable of high precision drug delivery, targeting tumor cell-dense areas of the brain.
Unlocking the future of cancer therapy
“Fluicell's patented technology offers unique opportunities to control fluid flow and drug delivery with ultra-high precision, enabling unique treatment solutions targeting serious disease.
By combining our technology with Ambusol's extensive expertise in cancer research, we are taking important steps forward to developing new treatments that can unlock groundbreaking new ways to treat cancer."
Carolina Trkulja, CEO Fluicell
Ambusol — Fueled by decades of cancer research
Ambusol is an innovative medical technology company founded by Professor Emeritus Gunnar Ronquist. The company focuses on developing and making available new and more gentle treatment methods for patients with Glioblastoma Multiforme (GBM), an aggressive form of brain tumor in stages 3 and 4. The goal is to improve the quality of life and prolong the lives of those affected, by offering an alternative treatment method that reduces the suffering that traditional treatments with chemotherapy and radiotherapy often entail.
Get in touch!
Want to learn about how we’re taking on cardiovascular disease?
Read more
Pipeline
Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.
our platform
Learn more about Nexocyte, Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.